An announcement from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has announced a webinar for shareholders and investors to discuss the latest business updates and answer frequently asked questions. This event, hosted by key executives, underscores the company’s commitment to transparency and engagement with stakeholders, potentially strengthening its industry position and stakeholder relations.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors. Their platform technologies aim to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than synthetically manufactured monoclonal antibodies and other immunotherapies. The company’s pipeline includes an allogeneic cell therapy CAR T drug targeting CD19 for blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers in combination with standard care drugs and emerging immunotherapies.
YTD Price Performance: 25.00%
Average Trading Volume: 140,174
Technical Sentiment Signal: Strong Buy
Current Market Cap: $107.4M
For an in-depth examination of IMU stock, go to TipRanks’ Stock Analysis page.